Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Pegvisomant and fasting both lead to GH resistance.

Who Took Part

The abstract describes 10 subjects taking part.

The age groups tagged for this paper are adults, men only.

The researchers also performed a single-arm open label study under nonfasting conditions in five of these subjects.

During the cross-over study, subjects fasted from 2400 h on day 1 until the end of the study.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label, placebo-controlled and crossover study.

The subjects were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the subjects nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the subjects and staff both knew the treatment.

Some subjects received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

On day 1, in random order, at 0800 h, a GHRP-6 or GHRH test was performed.

At 1600 h, a GHRH (if the first test was a GHRP-6 test) or GHRP-6-test (if the first test was a GHRH test) was done.

On day 4, GHRP-6 and GHRH tests were performed in the same order as on day 1.

During the GH stimulation tests, blood samples were drawn every 15 min from 15 to 120 min.

GH was determined in all samples.

What Was Measured

PubMed files the paper under topics including Area Under Curve, Fasting, Feedback, Growth Hormone, Growth Hormone-Releasing Hormone, Human Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.